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Abstract
Beta-amyloid 42 (A42) concentrations in cerebrospinal fluid (CSF) are significantly decreased in Alzheimer’s disease (AD). The aim
f this study was to correlate genetic variability in presenilin 2 (PSEN2) in relation to A42 concentrations and to confirm association of
apolipoprotein E (APOE) alleles E4/E4 genotype with lower CSF A42. Haplotype analysis of PSEN2 and APOE genotyping were
performed in 175 Alzheimer’s disease patients, as defined by clinical diagnosis and A42 levels. One distinct haploblock in PSEN2 was
detected and the frequent haplotypes were analyzed using 4 tagging single nucleotide polymorphisms (SNPs). We found an association
between haplotype 2 and higher CSF A42 concentrations (p  0.021) and lower A42 concentrations in haplotype 5 carriers (p  0.001).
POE E4/E4 carriers had lower A42 levels (p  0.009). Additive regression analysis showed an association of A42 level with APOE
genotype (p  0.024), haplotype 4 (p  0.064), and haplotype 5 (p  0.04), whereas gender, age at onset and Mini Mental State
Examination (MMSE) remained insignificant. Using CSF A42 as a biomarker we replicated genetic influences in APOE and observed a
significant influence of a new haplotype in PSEN2. A better understanding of genetic influences on biomarkers like CSF A42 might help
o stratify patients and develop specific treatment strategies.
2012 Elsevier Inc. All rights reserved.





Alzheimer’s disease (AD) is a neurodegenerative disor-
der characterized by a progressive cognitive deficit. It is the
most common cause of dementia in the elderly (Wimo et al.,
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fax: 49 731 500 63012.E-mail address: christine.arnim@uni-ulm.de (CAF von Arnim).
0197-4580/$ – see front matter © 2012 Elsevier Inc. All rights reserved.
doi:10.1016/j.neurobiolaging.2010.07.017003). In AD, aggregation of -amyloid (A) peptides of
different lengths leads to the formation of extracellular
amyloid plaques associated with neuronal death and synap-
tic loss (St George-Hyslop, 2000). The pathological beta-
amyloid 42 (A42) form of the -amyloid peptide is de-
ived by proteolytic processing from a neuronal membrane
rotein termed amyloid precursor protein (APP). The pro-
eolysis of APP is catalyzed by - and subsequently by
-secretases (Selkoe, 1994) leading to various lengths of



















































201.e10 E. Lebedeva et al. / Neurobiology of Aging 33 (2012) 201.e9–201.e18longer A42 peptide is more prone to aggregate in vitro and
s the type detected in the brains of AD patients (Iwatsubo
t al., 1994). Presenilins (PSEN) are the catalytic subunits of
he gamma-secretase complex (Wolfe et al., 1999). PSEN1
chromosomal localization on 14q24.3) and PSEN2 (1q31-
42) are homologous and share 62% amino acid identity.
he function of the PSEN1 -secretase catalyzing APP (and
lso Notch) cleavage is better understood than that of
SEN2. The knockout of PSEN1 lead to an embryonic
ethal phenotype and dramatically reduced A levels (Pa-
lacino et al., 2000; Shen et al., 1997) whereas the knockout
of PSEN2 in a mouse produced no specific phenotype and
essentially normal levels of A (Herreman et al., 1999).
A large number of mostly rare nonsynonymous muta-
tions were found in the APP, PSEN1, and PSEN2 genes.
Some of these variants cause familial AD (FAD) mostly of
the early onset type with fast disease progression (De
Strooper et al., 1998; Goate et al., 1991). So far 167 PSEN1
nonsynonymous mutations in 364 families and 10 PSEN2
mutations in 18 families have been identified (www.molgen.
ua.ac.be/ADMutations/ or www.alzgene.org).
The extracellular level and total brain amount of A42
as increased in transgenic mice brains expressing mutant
SEN1 and PSEN2 (Borchelt et al., 1996; Citron et al.,
997; Duff et al., 1996; Tomita et al., 1997; Xia et al.,
997). Presenilin mutations might cause FAD through a
ain of a deleterious function that elevates the amount of
xtraneuronal A42 (Borchelt et al., 1996; Citron et al.,
1997; Duff et al., 1996; Tomita et al., 1997; Xia et al.,
1997).
Despite the well characterized associations of some
PSEN and APP mutations with FAD, specific mutations
have not yet explained the majority of sporadic AD cases
showing a wide range in onset age (Bird et al., 1996).
Apolipoprotein E (APOE) allele E4 is the only consistently
confirmed genetic risk factor for sporadic AD.
Mechanisms leading to decreased concentrations of
A42 in cerebrospinal fluid (CSF) of sporadic AD patients
have not been clarified yet. Deposition of the peptide in the
plaques was suggested. However, this hypothesis cannot
fully explain the picture as a selective decrease of the
concentration of A42 in the CSF of patients with
reutzfeldt-Jakob disease as well as patients with bacterial
eningitis has been shown without development of any
myloid plaques at all (Sjogren et al., 2001; Wiltfang et al.,
003). Nevertheless, taken as a diagnostic biomarker for
D, cerebrospinal A42 discriminates AD from elderly
controls at quite high sensitivity and specificity (sensitivity
between 78% and 85% and specificity between 81% and
84%) (Blennow et al., 2001; Galasko et al., 1998; Hulstaert
et al., 1999; Lewczuk et al., 2004; Wiltfang et al., 2005) and
has been shown to inversely correlate with A deposition in
the brain in AD (Fagan et al., 2006).
It is currently unknown whether genetic polymorphisms
in PSEN1 and PSEN2 contribute to incidence and clinicalcourse of sporadic AD. It is also not known whether PSEN
polymorphisms are correlated with A42 concentrations in
SF.
According to the variations of A-peptide levels in dif-
erent laboratories (Lewczuk et al., 2004), in our laboratory
cutoff 600 pg/mL for the differential diagnostic question
AD vs. nondemented control) was established (Schöttle,
008). By defining an “A42 CSF-positive” phenotype
(cutoff below 600 pg/mL), we aimed at identifying novel
genetic modifiers for AD. As A42 levels predominantly
rely upon the activity of the active sites of -secretase,
resenilin 1 and 2, we therefore tested the hypothesis
hether rare frequent genetic haplotypes in PSEN2 are
ssociated with decreased A42 concentrations in CSF of
D patients compared with controls.
. Methods
.1. Patient samples
From 1999 to 2008, all patients who were diagnosed with
robable AD at the Memory Clinic of the Neurology Uni-
ersity Hospital of Ulm participated in the study. Diagnosis
as verified according to National Institute of Neurological
nd Communication Disorders Alzheimer’s Disease and
elated Disorders Association (NINCDS-ADRDA) criteria
nd the Diagnostic and Statistical Manual of Mental Disor-
ers, 4th Ed. (DSM-IV) (McKhann et al., 1984).
The patients gave written informed consent to participate
n the study and to have their clinical data documented
ogether with results from genetic analyses in genes poten-
ially relevant to AD. The study was approved by the uni-
ersity ethical review board (No. 2001/67).
Before diagnosis, subjects underwent a comprehensive
linical examination including their medical history, family
istory, a neurological and psychiatric examination, a rou-
ine blood analysis, a lumbar puncture with CSF analysis for
42 level, morphological imaging (magnetic resonance or
computed tomography [CT]), APOE genotyping, and a
comprehensive neuropsychological examination, including
Alzheimer’s disease Assessment Scale-cognitive subscale
(ADAS-cog). The degree of dementia was evaluated by the
Mini Mental State Examination (MMSE).
Subjects with AD diagnosis were included in the AD
group if the CSF A42 concentration was below the level of
00 pg/mL. CSF collection and preanalytical processing
ere performed using a standardized protocol in a clinical
outine setting as previously described (Brettschneider et
l., 2006). A42 measurement was performed using a com-
mercially available sandwich enzyme-linked immunosor-
bent assay (ELISA) (Innogenetics, Ghent, Belgium) accord-
ing to the manufacturer’s instructions.
2.2. Genetic analyses
DNA was isolated from its blood using QIAamp DNA
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performed on a GeneQuantpro RNA/DNA Calculator (Bio-
chrom, Cambridge, UK) measuring the absorbance value at
260 nm.
APOE genotypes of all the individuals and brain samples
were determined by the restriction of a polymerase chain
reaction (PCR) product with the enzyme HhaI as described
earlier (Wenham et al., 1991).
2.3. Haplotype analysis of PSEN2 gene
Haplotype analyses for PSEN2 was performed in order
to discriminate potentially functional haplotypes. Linkage
disequilibrium (LD) maps containing 30 polymorphisms for
the PSEN2 gene were generated from HapMap genotyping
data (www.hapmap.org, release 23 by March 2008) for the
EPH (Utah residents with ancestry from northern and
estern Europe) (abbreviation: CEU) population using
aploview 3.32 software (Haploview, www.broad.mit.edu/
pg/haploview). The term “CEPH” stands for the Centre
’Etude du Polymorphisme Humain, the organization that
ollected these samples in 1980.
The normalized disequilibrium coefficient D’ and loga-
ithm of the odds (LOD) were used as parameters to assess
he probability of 2 loci to be inherited together and the
evel of recombination between them. The maximum value
f D’ which is 1 indicates the complete LD between 2 loci.
he LOD value reflects the statistical significance for LD,
ith a LOD value of 2 indicating that odds are 100 to 1 in
avor of linkage.
Red and pink squares on the D=/LOD scheme correspond
o statistically significant LD between the pair of single
ucleotide polymorphisms (SNPs) (LOD  2) with the
aximum pairwise D= value for the red squares (D=  1).
hite squares indicate pairwise D= values lower than 1 with
o statistically significant evidence of LD (LOD  2). Blue
quares signify pairwise D= values of 1 but without statis-
ical significance (LOD  2). Haplotype block is depicted
s a black triangular comprising SNPs inherited together.
nly SNPs with the minor allele frequency higher than 5%
re depicted on the LD plot.
.4. Selection of tagging SNPs for PSEN2 gene
The squared correlation coefficient r2 is a measure of
tatistical association between 2 loci indicating the power to
etect an effect at 1 locus by typing another one, whereas D=
alue provides the information about the history of recom-
inations. Therefore r2 coefficients above 0.8 were used for
agging SNPs selection. Polymorphisms were selected
ased on the highest minor allele frequency and exonic
ocation.
.5. Genotyping of PSEN2 tagging SNPs
Predefined and validated assays for TaqMan real-time
CR were used for the genotyping of PSEN2 tagging
NPs (Applied Biosystems, Mannheim, Germany, Cata- togue number: rs2073489 [C_340454_1_], rs11405
C_340278_20], rs6759 [C_9633596_20], and rs1800680
C_9633614]). Each reaction consisted of 20 ng genomic
NA template, 6 L 2xTaqMan Universal PCR Master
ix, No AmpErase UNG®, and 0.3 L 40xTaqMan SNP
Genotyping Assay. TaqMan, Real-Time PCR was per-
formed under conditions described in the manufactured pro-
tocol: a preread run (allelic discrimination) at 60 °C, an
amplification run (absolute quantification) containing 10
minutes at 95 °C, 40 cycles of 92 °C for 15 seconds, and
60 °C for 1 minute, and a postread run (allelic discrimina-
tion) at 60 °C.
2.6. Statistical analysis
Statistical analysis was performed using the SPSS statis-
tical package version 12.0 (SPSS, Inc., Chicago, IL, USA).
The fit of genotype frequencies to the Hardy-Weinberg
equilibrium was tested by a 2 test. Differences in genotype
requencies in different subgroups were examined using a
earson 2 test. One-way analysis of variance (ANOVA)
est was used to assess the effects of genetic variants on
42 levels.
One-way analysis of variance was also used to evaluate
the strength of associations of A42 concentrations with
haplotype 2 and 5, APOE E4 allele, gender, and age at
disease onset. Additionally, effects of haplotypes were as-
sessed under an additive model, further including the APOE
genotype in the statistical model. Using a similar model
based on the number of haplotypes per individual, the as-
sociation of the 5 different haplotypes with A42 levels was
explored simultaneously, after choosing the most common
haplotype 1 as the reference haplotype. A value of p  0.05
was chosen as the cutoff level for statistical significance.
Table 1
Clinical characteristics of the patients diagnosed with Alzheimer’s
disease
Patient clinical characteristics




Age at onset, years 72.7  6.5
Mean CSF A42 level, pg/mL 407  105
MSE score 22.3  5.4
amily history
Relatives with AD 12 (8%)
Relatives with cognitive decline 29 (19%)




ey: A42, beta-amyloid 42; AD, Alzheimer’s disease; APOE, apolipo-
rotein E; CSF, cerebrospinal fluid; MMSE: Mini Mental State Examina-
ion; x, any other than APOE E4 allele.
201.e12 E. Lebedeva et al. / Neurobiology of Aging 33 (2012) 201.e9–201.e18Fig. 1. Linkage disequilibrium (LD) plot of presenilin 2 (PSEN2) obtained from HapMap: tagging single nucleotide polymorphisms (SNPs) are marked in
red. Each diagonal represents a definite SNP and each square indicates the pairwise magnitude of LD between 2 SNPs corresponding to the crossing diagonals.
In the table below the LD plot, the 5 most frequent haplotypes as defined by the tagging SNPs are shown including the haplotype frequency. The linkage
disequilibrium between the 4 tagging SNPs that were chosen is shown below using our own dataset. The numbers in the boxes representing the R2 values
of the linkage between each respective SNP.
and (c) for all haplotype combinations.
201.e13E. Lebedeva et al. / Neurobiology of Aging 33 (2012) 201.e9–201.e182.7. Comparison of results with publicly available
genotype data
To assess whether the SNPs tested in our biomarker
cohort also display evidence for genetic association with
AD risk in publicly available genotype data (e.g., originat-
ing from candidate gene studies or genome-wide association
studies [GWAS]), we consulted the AlzGene database (www.
alzgene.org), a publicly available online resource of genetic
association data in the field of AD (Bertram, 2007). Overall,
genotype data were available for all 4 of the haplotype-
defining SNPs tested here in at least 1 dataset. Whenever
more than 1 dataset was available, results were combined by
allele-based random-effects meta-analyses (see Bertram,
2007 for details). Note that exact haplotype reconstruction
was not possible as there was no single dataset with geno-
type data available for all 4 haplotype-defining SNPs or
their proxies.
3. Results
The AD group included 175 individuals (106 female and
69 male) with a mean age of 73 ranging from 60 to 87 years.
MMSE score was 22.3  5.4 (mean  standard deviation).
Family history was available for 152 individuals with 8%
having a well-confirmed positive AD family history and
19% having relatives with cognitive decline symptoms. The
clinical characteristics of the patients are summarized in
Table 1.
The range of A42 concentrations in the CSF in the AD
patients was 176 to 598 pg/mL.
The APOE E4 allele frequency was 43.6%, 49.7% of
patients were heterozygous carriers of the APOE E4 allele
and 18.8% were homozygous carriers. There were no sig-
nificant difference in the APOE E4 allele frequency be-
tween males and females (data not shown).
3.1. Haplotype analysis of PSEN2
The major PSEN2 haplotype block containing 19 SNPs
covered a 23-kb region. A second minor block had 2 SNPs
which were less than 1 kb apart. Both SNPs in the minor
block were 100% linked to haplotypes of the major haplo-
block, thus, the smaller haploblock was not analyzed sepa-
rately. The major 23 kb haploblock which is comprised of
98% of all possible combinations of SNPs was chosen for
the selection of tagging SNPs.
Four SNPs, rs2073489, rs11405, rs6759, and rs1800680
served as tagging SNPs coding for the 5 most frequent
PSEN2 haplotypes (Fig. 1).
Rs11405 and rs6759 lead to synonymous amino acid
substitutions Ala23Ala and Asn43Asn in the Exon 3 of
the PSEN2 gene. Rs2073489 is an intron 2 C to T ex-
change; rs1800680 G to A substitution is located in the
intron 6.Fig. 2. A box plot graph showing the median (black), the 25th and 75th
percentile (boxes) and the data range (antennas) of the beta-amyloid 42
(A42) values in cerebrospinal fluid (CSF). (a) A42 in heterozygous and
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concentrations in CSF
Table 1 shows the clinical characteristics of the patients,
and the distribution of the APOE genotypes.
We analyzed the A42 CSF concentrations in homozy-
ous, heterozygous, and noncarriers of each PSEN2 haplo-
ype (Fig. 2, Table 2). Higher A42 concentrations in CSF
were detected with increasing copy numbers of haplotype 2
(p  0.021, ANOVA) with mean levels of 399, 408, and
494 pg/mL in carriers of none, 1, or two haplotypes 2 (Fig.
2a and c). Under the additive model for haplotype 2, in-
cluding APOE genotype, this association was confirmed
(p  0.037). Only analyzing rs6759, a similar association
with higher A42 in homozygous carriers but not in
eterozygous carriers was visible in the patients, (p 0.01).
o difference in MMSE or age of onset of disease was
bserved in the haplotype 2 carriers compared with noncar-
iers.
Further, an association between haplotype 5 (rs1800680)
nd lower A42 concentrations in heterozygous carriers
able 2
SEN2 haplotypes and correlation with A42 CSF level in (p-values are












TCTG 0 98 400.95  104.14 0.092
1 64 404.52  108.205
2 13 467.85  73.99
Haplotype 2
CCCG 0 107 398.80  110.25 0.021
1 58 407.76  93.43
2 10 494.30  64.97
Haplotype 3
CCTG 0 137 403.24  103.80 0.472
1 32 427.28  103.06
2 6 391.33  138.80
Haplotype 4
(rs11405)
CTCG 0 104 420.53  103.08 0.097
1 69 386.20  105.39
2 2 440.50  79.90
Haplotype 5
(rs1800680)
TCTA 0 115 427.50  98.35 0.001
1 55 364.44  108.05
2 5 411.64  80.89
Rs2073489
CC 0 55 427.62  97.35 0.142
CT 1 86 392.31  107.41
TT 2 34 411.95  106.21
Rs6759
TT 0 57 419.90  113.97 0.01
TC 1 84 383.95  96.00
CC 2 34 443.47  97.81
Key: A42, beta-amyloid 42; AD, Alzheimer’s disease; ANOVA, analysis
f variance; APOE, apolipoprotein E; CSF, cerebrospinal fluid; PSEN2,
resenilin 2.was observed. However this effect was less in the 5 indi- gviduals who were homozygous haplotype 5 carriers (means
of 428 vs. 364, and 412 pg/mL in homozygous carriers, p
0.001, Fig. 2b and c). An analysis taking into account APOE
genotype yielded comparable results where p  0.0003.
There was a significantly lower A42 concentrations in
CSF in homozygous carriers of the APOE E4 allele than in
the heterozygous or non-E4 carriers (361 pg/mL in homozy-
gous allele 4 carriers vs. 430 pg/mL in heterozygous and
398 pg/mL in non-E4 carriers p 0.009, ANOVA) (Fig. 3a
and b).
Looking at clinical correlations with A42, we observed
ignificant positive correlation between A42 CSF concen-
rations and MMSE value in the whole AD group (r 
.173, p  0.032). Although there was a slightly higher
ercentage of females in the AD group (60%) there was no
ssociation between sex and A42 levels in CSF. There was
Fig. 3. (a) Beta-amyloid 42 (A42) for apolipoprotein E (APOE) different
enotypes; (b) depicts A42 for APOE E4 allele non-carriers (0), heterozy-
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and A42 concentrations in CSF.
For explorative analysis of single effects of genotypes or
clinical variables on A variability, univariate ANOVAs
ere performed. Additionally, additive models were applied
here the per-allele effects at single SNPs were investi-
ated. After this, the variables found to be significant were
ncluded in the multifactorial model, in addition to the
ignificant covariates.
After exploratory analysis of the single factors in a uni-
ariate model, we analyzed the number of haplotypes to-
ether with all significant covariates (which were significant
n the univariate model), based on an additive regression
odel. In this model, we chose haplotype 1 as the reference
aplotype and included the numbers of the other haplotypes
haplotype 2–5) per individual as factors in the model. The
ovariates included were gender, APOE genotype, MMSE,
nd age of onset (AAO). In this model, significant effects on
42 were observed for APOE genotype (p  0.024),
haplotype 4 (p  0.064), and haplotype 5 (p  0.04),
whereas gender, age of onset, and MMSE remained insig-
nificant.
In a simultaneous analysis of all haplotypes in relation to
reference haplotype 1 in one additive statistical model under
consideration of the APOE genotype, significant effects on
A42 were observed for APOE genotype (p  0.007),
haplotype 4 (p  0.063), and haplotype 5 (p  0.0009).
Gender, age of onset, and MMSE had been excluded from
the model beforehand due to insignificant association with
A42.
Finally, we investigated whether any of the 4 tested SNPs
showed evidence for association with AD risk in publicly
available genotype data extracted from the AlzGene database
(Supplementary Table 1). With the possible exception of
rs11405 (which defines haplotype 4; p-value 0.15) there was
o evidence supporting a correlation of these SNPs with dis-
ase risk. It should be noted, however, that quantitative trait
nalyses on CSF A42 levels cannot be directly compared
with results obtained from investigating binary endpoints such
as AD vs. no AD. Furthermore, and probably more impor-
tantly, only haplotypes 4 and 5 could be assessed in this way
due to the lack of sufficient genotype data in the available
datasets. Therefore, more extensive de novo genotyping will be
necessary to independently replicate our findings.
4. Discussion
While genetic variations in presenilin genes are known to
influence familial Alzheimer’s disease, the genetic under-
pinnings for sporadic cases are less characterized. Because
A42 concentrations in CSF are used as a biological marker
for severity of AD, our intention was to analyze associations
between genetic variants in presenilin genes and the A42
oncentrations in AD patients.We studied the correlation between PSEN2 haplotypes
nd A42 concentrations in CSF because low levels of
42, and high level of tau-protein are used as a biomarker
for AD (Otto et al., 2008; Skoog et al., 2003), and preseni-
lin-dependent -cleavage is the last step in A-production.
correlation between a lower A42 concentration in CSF
and greater cognitive decline as well as a higher abundance
of amyloid plaques in the brain has been shown (Fagan et
al., 2007; Gustafson et al., 2007; Stomrud et al., 2007). It is
known that PSEN1 and 2 mutation carriers show decreased
Abeta levels (Nikisch et al., 2008; Portelius et al., 2010;
Uttner et al., 2010). However little is known about reasons
for and significance of variations of A42 in sporadic AD
atients.
A certain stability over time of this marker has been
hown with no consistent change of the CSF A42 level of
atients during month 10 and month 20 indicating that
easuring A42 might serve as a kind of biological marker
for Alzheimer disease (Andreasen et al., 1999).
We were able to replicate prior findings of APOE E4
genotype association with decreased A42 levels in CSF in
poradic AD patients (Prince et al., 2004; Sunderland et al.,
004).
PSEN2 haplotypes were analyzed by 4 tagging SNPs
n their relation to CSF A42 concentrations in AD
atients. In addition to APOE, a significant influence of
he rs1800680 defining haplotype 5 of PSEN2 on A42
was detected with lower A42 in carriers than in non-
carriers. Recently, PSEN2 was also studied in relation to
schizophrenia because it lies in a schizophrenia suscep-
tibility locus (Zhang et al., 2009) and an influence of
rs6759 and rs11405 on mRNA (messenger ribonucleic
acid) expression in blood lymphocytes from schizo-
phrenic patients but not in healthy controls, and an asso-
ciation with the rs1295645 and schizophrenic symptoms
(Zhang et al., 2009). In our analysis, only the rs1800680
which is in no LD with any of the SNPs studied in this
analysis on schizophrenia showed a significant effect on
A42.
The reason to choose PSEN2 and not PSEN1 was the
nding that in the PSEN1 gene, there are no distinct regions
f high LD resulting in few distinct haplotype blocks but in
large number of possible combinations of variants.
A recent study investigating the association between
SEN1 variants and the risk for AD development, revealed
marginally significant protective effect of the intronic
s165932 G allele (p  0.03) (Belbin et al., 2008). Even
hough the approach to choose the most frequent variants in
gene for genotyping may cover the most frequent genetic
onstellations (as combinations of the respective variants),
he lack of distinct haplotype blocks with numerous variants
auses significant multiple testing problems.
Our study suggests that the AD association with
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represents a false positive finding altogether. There are a
number of limitations of the present analysis. First, due to
the cross-sectional design, no follow-up of the A42
levels exists. Thus, we could not account for the changes
in A42 over the time. Second, we do not have longitu-
dinal clinical data. As we found no association with
gender, APOE genotype, MMSE score, and AAO, anal-
ysis of associations with longitudinal parameters like
disease progress or parameters like efficacy of medica-
tion will be a topic in future studies. However, it is
known from the familial AD cases carrying PSEN muta-
tions that AAO exhibits a wide range and other genes
modifying AAO are discussed in this context (Pastor et
al., 2003). MMSE itself decreases over time in contrast to
the genetic factors analyzed here. Therefore an associa-
tion with MMSE would be surprising. As now first trials
with amyloid modifying drugs are conducted analyses of
responders regarding their PSEN2 haplotype might be of
particular interest. Third, we do not have imaging data,
because it has been shown that PSEN2 SNPs are associ-
ated with alterations is gray matter density and hip-
pocampal volume in magnetic resonance imaging (MRI)
(Sloan et al., 2010).
Finally, despite the strong statistical support for the associ-
ations between CSF Abeta levels and PSEN2, these findings
have to be confirmed in other CSF based studies and the
relevance on a population-wide level remains to be deter-
mined.
This study was indeed a replication for the previous studies
on the relation between APOE genotype and A42, and, sim-
lar, an independent replication of this finding on haplotype 5
ould be desired.
Taken together, the associations described will likely have
o major role serving as a diagnostic or predictive tool for AD
n a clinical setting, unless other (e.g., rarer) variants of higher
enetrance are linked to the observed effects. However, and
epending on their exact functional role in AD pathogenesis,
he identified haplotypes might still be essential in advancing
ur understanding of the biochemical processes leading to AD.
better understanding of genetic influences on biomarkers
ike CSF A42 might help to develop appropriate and effective
means to target these processes therapeutically.
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